M. Albulescu

A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity

U. Müller-Ladner, Isharat Yusuf, T. Thisted, 2019, Science Translational Medicine.

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

I. Bruce, K. Kalunian, E. Morand, 2022, Annals of the Rheumatic Diseases.

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody

J. Kremer, M. Weinblatt, J. Vencovský, 2018, Arthritis & rheumatology.

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis

J. Kremer, M. Weinblatt, J. Vencovský, 2017, Arthritis & rheumatology.